Antiviral activity of Shiga toxin

Details Antiviral activity of Shiga toxin Antiviral activity of Shiga toxin

2006-11-14

2006-11-14

Campbell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

C424S236100, C514S002600, C530S300000, C530S350000

Reexamination Certificate

active

07135173

ABSTRACT:
The present invention provides methods and compositions for eliminating virally-infected cells by administering a Shiga-toxin composition, and the present invention provides methods and compositions for suppressing bovine leukemia-related cell proliferation. In the methods, a Shiga-toxin composition is administered in an amount effective to suppress bovine leukemia-related cell proliferation. The Shiga-toxin composition can include a Shiga-toxin polypeptide; a probiotic microorganism expressing a Shiga-toxin polypeptide; or a transgenic plant expressing a Shiga-toxin polypeptide. In one embodiment, the Shiga-toxin polypeptide is Stx1A and, in another embodiment, the Shiga-toxin polypeptide is Stx1 holotoxin. In yet a further embodiment, the Shiga-toxin polypeptide comprises Stx2.

REFERENCES:
patent: 4724205 (1988-02-01), Karlsson et al.
patent: 4859769 (1989-08-01), Karlsson et al.
patent: 5204097 (1993-04-01), Arnon et al.
patent: 5220014 (1993-06-01), Ackerman et al.
patent: 5378688 (1995-01-01), Nett et al.
patent: 5552144 (1996-09-01), Samuel et al.
patent: 5552294 (1996-09-01), Thorne
patent: 5620858 (1997-04-01), Armstrong et al.
patent: 5645836 (1997-07-01), Kitto
patent: 5679653 (1997-10-01), Armstrong et al.
patent: 5744580 (1998-04-01), Better et al.
patent: 5747028 (1998-05-01), Calderwood
patent: 5756699 (1998-05-01), Better et al.
patent: 5762941 (1998-06-01), Sansonetti et al.
patent: 5795717 (1998-08-01), Nakayama et al.
patent: 5801145 (1998-09-01), Gariépy
patent: 5807879 (1998-09-01), Rosebrough
patent: 5837491 (1998-11-01), Better et al.
patent: 5849714 (1998-12-01), Rafter et al.
patent: 5888750 (1999-03-01), Vanmaele et al.
patent: 5922848 (1999-07-01), Vanmaele et al.
patent: 5955293 (1999-09-01), Keusch et al.
patent: 5955449 (1999-09-01), Armstrong et al.
patent: 5962423 (1999-10-01), Bundle et al.
patent: 5965128 (1999-10-01), Doyle et al.
patent: 5965406 (1999-10-01), Murphy
patent: 5968894 (1999-10-01), Lingwood et al.
patent: 5981568 (1999-11-01), Kunz et al.
patent: 6013506 (2000-01-01), Wardley et al.
patent: 6015897 (2000-01-01), Theodore et al.
patent: 6018022 (2000-01-01), Read et al.
patent: 6627197 (2003-09-01), Keener et al.
Basu et al., Infection and Immunity vol. 71 No. 1, pp. 327-334 (Jan. 2003).
Hino et al., Journal of Infectious Diseases, Colume 157 No. 6, pp. 1270-1271 (Jun. 1988).
Samuel et al., Journal of Biological Chemistry, vol. 267, No. 7, pp. 4853-4859 (Feb. 1994).
Haddad et al., Journal of Bacteriology, vol. 175 No. 16, pp. 4970-4978 (Aug. 1993).
Girbés et al., Journal of Biological Chemistry, vol. 268 No. 24, pp. 18195-18199 (Aug. 1993).
Al-Jaufy et al., Infection and Immunity, vol. 63 No. 8, pp. 3073-3078 (Aug. 1995).
Al-Jaufy et al., Infection and Immunity, vol. 62 No. 3, pp. 956-960 (Mar. 1994).
Skinner et al., Microbial Pathogenesis, vol. 24 No. 2, pp. 117-122 (Feb. 1998).
Fernández-Puentes et al., Cell, vol. 20 No. 3, pp. 769-775 (Jul. 1980).
Gatei et al., Journal of Virology, vol. 67 No. 4, pp. 1803-1810 (Apr. 1993).
Saxena et al., The Journal of Biological Chemistry, vol. 264 No. 1, pp. 596-601 (Jan. 1989).
Noakes et al., FEBS Letters, vol. 453 Nos. 1-2, pp. 95-99 (Jun. 1999).
LaCasse et al., Blood, vol. 94 No. 8, pp. 2901-2910 (Oct. 1998).
definition “receptor,” Lodish et al., Molecular Cell Biology, Third Edition, Scientific American Books, NY, 1995, p. G-15.
definition “receptor,” Wikipedia, the Free Encyclopedia, wikipedia.org. (2005).
definition “receptor,” The On-Line Medical Dictionary, cancerweb.ncl.ac.uk/omd. (2003).
Arroyo, J., et al., “Membrane Permeabilization by Different Regions of the Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein gp41,”Journal of Virology 69(7):4095-4102, Jul. 1995.
Austin, P.R., and C.J. Hovde, “Purification of Recombinant Shiga-like Toxin Type I B Subunit,”Protein Expression and Purifications 6:771-779, 1995.
Austin, P.R., et al., “Evidence That the A2Fragment of Shiga-Like Toxin Type I is Required for Holotoxin Integrity,”Infection and Immunity 62(5):1768-1775, May 1994.
Baliga, V., and J.F. Ferrer, “Expression of the Bovine Leukemia Virus and its Internal Antigen in Blood Lymphocytes,”Proceedings of the Society for Experimental Biology and Medicine 156:388-391, 1977.
Barnett, B., et al., “Antiviral Immunotoxins: Antibody-Mediated Delivery of Gelonin Inhibits Pichinde Virus Replication In Vitro,”Antiviral Research 15(2):125-138, Feb. 1991.
Bast, D.J., et al., “Murine Antibody Responses to the Verotoxin 1 B Subunit: Demonstration of Major Histocompatibility Complex Dependence and an Immunodominant Epitope Involving Phenylalanine 30,”Infection and Immunity 65(7):2978-2982, Jul. 1997.
Benigni, F., et al., “Preclinical evaluation of the ribosome-inactivating proteins PAP-1, PAP-S, and RTA in mice,”Int. J. Immunopharmacol. 17(10):829-839, 1995. (Abstract).
Bodelón, G., et al., “Modification of Late Membrane Permeability in Avian Reovirus-Infected Cells,”Journal of Biological Chemistry 277(20):17789-17796, May 17, 2002.
Bruck, C., et al., “Biologically Active Epitopes of Bovine Leukemia Virus Glycoprotein GP51: Their Dependence on Protein Glycosylation and Genetic Variablity,”Virology 136:20-31, 1984.
Carrasco, L., “Modification of Membrane Permeability by Animal Viruses,”Advances in Virus Research 45:61-112, 1995.
Ciccaglione, A.R., et al., “Mutagenesis of Hepatitis C Virus E1 Protein Affects its Membrane-Permeabilizing Activity,”Journal of General Virology 82:2243-2250, 2001.
Donohue-Rolfe, A., et al., “Shiga Toxin: Purification, Structure, and Function,”Reviews of Infectious Diseases 13(Suppl. 4):S293-S297, 1991.
Dosio F., et al., “A New Approach in the Synthesis of Immunotoins: Ribosome Inactivating Protein Noncovalently Bound to Monoclonal Antibody,”Journal of Pharmaceutical Sciences 83(2):206-211, Feb. 1994.
Driscoll, D.M., et al., “Inhibition of Bovine Leukemia Virus Release by Antiviral Antibodies,”Arch. Virol. 55(1-2):139-144, 1977.
Ferens, W.A. and C.J. Hovde, “Antiviral Activity of Shiga Toxin 1: Suppression of Bovine Leukemia Virus-Related Spontaneous Lymphocyte Proliferation,”Infection and Immunity 68(8):4462-4469, Aug. 2000.
Girbés, T., et al., “Recent Advances in the Uses and Applications of Ribosome-Inactivating Proteins From Plants,”Cellular and Molecular Biology 42(4):461-471, Jun. 1996.
Gupta, p., et al., “Transcriptional Control of the Bovine Leukemia Virus Genome: Role and Characterization of a Nonimmunoglobulin Plasma Protein From Bovine Leukemia Virus-Infected Cattle,”Journal of Virology 50(1):267-270, 1984.
Hassan, S.H., et al., “Expression and Functional Characterization of Bluetongue Virus VP5 Protein: Role in Cellular Permeabilization,”Journal of= Virology 75(18):8356-8367, Sep. 2001.
Hovde, C.J., et al., “Evidence That Glutamine Acid 167 is an Active-Site Residue of Shiga-Like Toxin, ”Proc. Natl. Acad. Sci. USA 85:2568-2572, 1988.
Jensen, W.A., et al., “In VitroExpression of Bovine Leukemia Virus in Isolated B-Lymphocytes of Cattle and Sheep,”Veterinary Immunology and Immunopathology 26:333-342, 1990.
Kidd, L.C., and K. Radke, “Lymphocyte Activators Elicit Bovine Leukemia Virus Expression Differently as Asymptomatic Infection Progresses,”Virology 217:167-177, 1996.
Menge, C., et al., “Shiga Toxin 1 FromEscherichia ColiBlocks Activation and Proliferation of Bovine Lymphocyte SubpopulationsIn Vitro,” Infection and Immunity 67(5):2209-2217, May 1999.
Mirsky, M.L., et al., “The Prevalence of Proviral Bovine Leukemia Virus in Peripheral Blood Mononuclear Cells at Two Subclinal Stages of Infection,” Journal of Virology70(4):2178-2183, Apr. 1996.
Paton, A.W., et al., “Neutralization of Shiga Toxins Stx1, Stx2c, and Stx2e by Recombinant Bacteria expressing Mimics of

Affiliated with

Also associated with

Rating

Antiviral activity of Shiga toxin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antiviral activity of Shiga toxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral activity of Shiga toxin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3673178